Table 3.

Nutritional parameters; safety set

	Dose-titration phase (n= 39)	Parallel-group phase
		Lanthanum carbonate (n= 10)	Placebo (n= 11)
Weight, kg
Start of dose-titration phase	76.2 (14.1)	–	–
Start of parallel-group phase	74.9 (13.5)a	73.2 (16.0)	74.1 (12.0)
End of parallel-group phase	–	73.2 (17.0)	73.4 (13.6)b
Total serum protein, g/dl
Start of dose-titration phase	6.9 (0.8)	6.7 (1.0)	6.9 (0.7)
Start of parallel-group phase	6.8 (0.7)c	6.6 (0.9)	6.9 (0.4)
End of parallel-group phase	–	6.9 (0.7)	6.7 (0.7)d
Serum albumin, g/dl
Start of dose-titration phase	3.8 (0.4)	3.7 (0.4)	4.0 (0.3)
Start of parallel-group phase	3.7 (0.3)c	3.6 (0.4)	3.9 (0.3)
End of parallel-group phase	–	3.7 (0.4)	3.6 (0.4)e

Data are presented as mean (standard deviation).

^an = 25; ^bn = 9; ^cn = 31; ^dn = 7; ^en = 8.